Skip to main
VYGR
VYGR logo

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc possesses a robust pipeline of potential gene therapies aimed at severe neurological diseases, emphasizing the significance of their TRACER platform for developing AAV-based gene therapies that may yield durable efficacy. The company's co-commercialization options for key programs could augment long-term revenue potential, while the favorable safety profile bolstered by the absence of serious adverse events supports a positive assessment of their clinical progress. Additionally, the extended cash runway into mid-2027, following adjustments in their development strategy, enables Voyager to focus on advancing its promising Alzheimer's programs, further enhancing the investment thesis for shareholders.

Bears say

Voyager Therapeutics Inc is currently not generating sales revenue and faces significant challenges, as it may take many years for the company to achieve profitability, highlighted by a reported net loss of ($1.13) per basic and diluted share for the year. The company is exposed to regulatory and clinical risks, as any failure in producing sufficient products for clinical studies, delays in approval, or unfavorable study outcomes could adversely impact revenue projections and overall valuation estimates. Furthermore, Voyager's competitive position is precarious, with multiple tau antibody programs ahead of its candidate VY7523, requiring a strong efficacy and safety profile to capture market share, amid the inherent risks of clinical trial failures and slow enrollment.

Voyager Therapeutics (VYGR) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 20 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Sep 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.59, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.59, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.